Biosimilars: From Science to Practice in Cancer Care
This course will start by explaining the difference between chemical and biologic drugs and build up so that any working pharmacist can describe the studies involved in approvals. By the end of the course, pharmacists working in practice will be guided to develop their own implementation plans using expert advice and learning from the United Kingdom.
This three-part, flexible course will take up to 6 hours in total to complete and by the end, you will have developed a plan for the setting you practice in to rapidly adopt a biosimilar medicine and maximise the cost savings for your workplace. The learning will consist of reading, activities as well as time to develop your own plans and collaborate with others internationally.
The course is developed and accredited by UCL School of Pharmacy, one of the top ten pharmacy schools in the world (QS World University Rankings 2021) and a certificate of completion will be issued to all participants.
On completion of the eLearning module, you will be able to:
- Demonstrate your understanding of the difference between biologic and chemical drugs.
- Improve your understanding of biosimilars vs generics in terms of characteristics of structure and the clinical trials required.
- Demonstrate knowledge of comparability studies and regulatory data.
- Improve knowledge of practical aspects of adopting biosimilars – storage and stability differences.
- Show understanding of patient considerations eg. revised consent, adverse reactions and patient information.
- Improve confidence in handling clinician concerns prior to uptake.
Join this course
The course is free to access. Please click here to enrol. You will be taken to a webpage where you need to click 'Select'. After this you will need to log in if you have a UCL Extend Account, or create a new account.
If you have any queries about the course please contact Pinkie Chambers at email@example.com
Follow the Twitter handle @UCLbiosimilar to join in with the discussion, ask questions and stay up to date with recent developments.